Concepedia

Jim Marsters

JM

Statistics

Publications

4

Citations

221

H-Index

4

Active since

2003

Affiliations

University of Oklahoma Health Sciences Center(Current)

Sarah Cannon

Harvard University

Dana-Farber Cancer Institute

Tennessee Oncology

Jim Marsters is an author at University of Oklahoma Health Sciences Center specializing in medicine, oncology, and pharmacology.

Publications per year

2003–2020

4

Publications

4

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Susana Banerjee, Amit M. Oza, Michael J. Birrer et al. · Annals of Oncology · 2018 · 98 citations · Full text

, , +16

Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.

Nerissa Mendoza, Sharon Fong, Jim Marsters et al. · PubMed · 2003 · 69 citations

, , +17

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer

Kathleen N. Moore, Michael J. Birrer, Jim Marsters et al. · Gynecologic Oncology · 2020 · 32 citations · Full text

, , +17

A paracrine requirement for Hedgehog signaling in cancer

Robert L. Yauch, Stephen E. Gould, Derek Marshall et al. · 2008 · 22 citations

, , +17

1–4 of 4